The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment

被引:4
|
作者
Dehghan, Razieh [1 ]
Bahreini, Fatemeh [1 ]
Najafi, Rezvan [1 ]
Saidijam, Massoud [1 ]
Amini, Razieh [1 ]
机构
[1] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; SIGNALING PATHWAY; 5-FLUOROURACIL; APOPTOSIS; SURVIVIN; CHEMOSENSITIZATION; CHEMORESISTANCE; SENSITIVITY; SUPPRESSION;
D O I
10.1155/2021/6635874
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives. Chemotherapy is considered to be essential in the treatment of patients with colorectal cancer (CRC), but drug resistance reduces its efficacy. Many patients with advanced CRC eventually show resistance to 5-fluorouracil (5-FU) therapy. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients' response. Zerumbone (ZER), which is derived from ginger, has been studied for its growth inhibitory function in various types of cancer. Methods. The cytotoxic effects of ZER and 5-FU alone and their combination, on the SW48 and HCT-116 cells, were examined, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The mRNA and protein levels of beta-catenin, survivin, and vimentin were measured in treated CRC cells, using qRT-PCR and western blot. Colony formation assay, scratch test, and flow cytometry were performed to detect the changes of proliferation, migration, and apoptosis. Key Findings. In HCT-116- and SW48-treated cells, the proliferation, the gene and protein expression levels of the markers, the migration, the colony formation, and the survival rates were all significantly reduced compared to the control groups, and the sharpest decline was observed in the 5-FU+ZER treatment groups. Conclusions. Combination therapy has shown promising results in CRC cells, especially in drug-resistant cells.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells
    Li, Fangzhou
    Qiu, Fen
    Fan, Xu
    Yu, Qingqing
    Liu, Shuaitong
    Guo, Yang
    Zhu, Yunhe
    Xi, Xueyan
    Du, Boyu
    GENE, 2024, 892
  • [22] Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
    Zhang, Qian
    Liu, Rui-Xian
    Chan, Ka-Wo
    Hu, Jiancong
    Zhang, Jingdan
    Wei, Lili
    Tan, Huiliu
    Yang, Xiangling
    Liu, Huanliang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [23] Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism
    Zhao, Jun-gang
    Ren, Kai-ming
    Tang, Jun
    TUMOR BIOLOGY, 2014, 35 (12) : 12305 - 12315
  • [24] Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell
    Buse Ardıl
    Mehlika Alper
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 1109 - 1123
  • [25] Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
    Wang, Weicheng
    Guo, Wenjie
    Li, Lele
    Fu, Zan
    Liu, Wen
    Gao, Jian
    Shu, Yongqian
    Xu, Qiang
    Sun, Yang
    Gu, Yanhong
    BIOCHEMICAL PHARMACOLOGY, 2016, 121 : 8 - 17
  • [26] Role of Caspases in 5-FU and Selenium-induced Growth Inhibition of Colorectal Cancer Cells
    Thant, Aye Aye
    Wu, Yanyuan
    Lee, Jane
    Mishra, Dhruva Kumar
    Garcia, Heather
    Koeffler, H. Phillip
    Vadgama, Jaydutt V.
    ANTICANCER RESEARCH, 2008, 28 (6A) : 3579 - 3592
  • [27] A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment
    Huang, Chi-Jung
    Yang, Shung-Haur
    Huang, Shih-Ming
    Lin, Chih-Ming
    Chien, Chih-Cheng
    Chen, Yan-Chu
    Lee, Chia-Long
    Wu, Hao-Han
    Chang, Chun-Chao
    JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9
  • [28] Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell
    Ardil, Buse
    Alper, Mehlika
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (09) : 1109 - 1123
  • [29] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [30] 5-FU VERSUS COMBINATION THERAPY WITH TUBERCIDIN, STREPTOZOTOCIN, AND 5-FU IN THE TREATMENT OF PANCREATIC CARCINOMAS - COG PROTOCOL-7230
    AWRICH, A
    FLETCHER, WS
    KLOTZ, JH
    MINTON, JP
    HILL, GJ
    AUST, JB
    GRAGE, TB
    MULTHAUF, PM
    JOURNAL OF SURGICAL ONCOLOGY, 1979, 12 (03) : 267 - 273